ArticleJournal of cardiovascular translational research2018
Development of a Novel Human Cell-Derived Tissue-Engineered Heart Valve for Transcatheter Aortic Valve Replacement: an In Vitro and In Vivo Feasibility Study.
Article in Journal of cardiovascular translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- MSC Origin and Biomechanical Conditioning Determine ECM Maturation in Tissue-Engineered Matrix.Biomedicines · 2026Article
- Combining genome and tissue engineering for next-generation human biomimetics.Stem cells translational medicine · 2025Article
- Development of transcatheter implantable autologous tissue-engineered pulmonary valves using in-body tissue architecture.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Article
- Smooth leaflets with curved belly and attachment edge profiles promote adaptive remodeling in tissue-engineered heart valves: an in silico study.Biomechanics and modeling in mechanobiology · 2025Article
- Prosthetic Heart Valves: More than Half a Century of Innovation-An Overview.Journal of clinical medicine · 2025Review
- A chronological history of heart valve prostheses to offer perspectives of their limitations.Frontiers in bioengineering and biotechnology · 2025Review
- Development of an iPSC-derived tissue-resident macrophage-based platform for the in vitro immunocompatibility assessment of human tissue engineered matrices.Scientific reports · 2024Article
- Evaluation of pliable bioresorbable, elastomeric aortic valve prostheses in sheep during 12 months post implantation.Communications biology · 2023Article
- Valvulogenesis of a living, innervated pulmonary root induced by an acellular scaffold.Communications biology · 2023Article
- Combining Cell Technologies With Biomimetic Tissue Engineering Applications: A New Paradigm for Translational Cardiovascular Therapies.Stem cells translational medicine · 2023Review
- Biological Scaffolds for Congenital Heart Disease.Bioengineering (Basel, Switzerland) · 2023Review
- A European update on transcatheter aortic valve implantation (TAVI) in the COVID era.Journal of anatomy · 2023Review
- Macrophage-extracellular matrix interactions: Perspectives for tissue engineered heart valve remodeling.Frontiers in cardiovascular medicine · 2022Review
- Endothelial Progenitor Cell-BasedFrontiers in bioengineering and biotechnology · 2022Article
- Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity.Nature reviews. Cardiology · 2021Review
- Human iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering.Frontiers in cell and developmental biology · 2021Review
- Progressive Reinvention or Destination Lost? Half a Century of Cardiovascular Tissue Engineering.Frontiers in cardiovascular medicine · 2020Review
- Stiff Composite Cylinders for Extremely Expandable Structures.Scientific reports · 2019Article
- Human cell-derived tissue-engineered heart valve with integrated Valsalva sinuses: towards native-like transcatheter pulmonary valve replacements.NPJ Regenerative medicine · 2019Article
- Preclinical Assessment of Cardiac Valve Substitutes: Current Status and Considerations for Engineered Tissue Heart Valves.Frontiers in cardiovascular medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter aortic valve replacement (TAVR) is being extended to younger patients. However, TAVR-compatible bioprostheses are based on xenogeneic materials with limited durability. Off-the-shelf tissue-engineered heart valves (TEHVs) with remodeling capacity may overcome the shortcomings of current TAVR devices. Here, we develop for the first time a TEHV for TAVR, based on human cell-derived extracellular matrix and integrated into a state-of-the-art stent for TAVR. The TEHVs, characterized by a dense acellular collagenous matrix, demonstrated in vitro functionality under aortic pressure conditions (n = 4). Next, transapical TAVR feasibility and in vivo TEHV functionality were assessed in acute studies (n = 5) in sheep. The valves successfully coped with the aortic environment, showing normal leaflet motion, free coronary flow, and absence of stenosis or paravalvular leak. At explantation, TEHVs presented full structural integrity and initial cell infiltration. Its long-term performance proven, such TEHV could fulfill the need for next-generation lifelong TAVR prostheses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.